Housing AstraZeneca's old R&D efforts in antibiotics, Entasis files for $86M IPO
When AstraZeneca spun out its struggling antibiotics unit a few years back, the tech — and a much smaller team — was deposited into a company called …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
